Stockreport

Candel Therapeutics reports Q3 results [Seeking Alpha]

Candel Therapeutics, Inc.  (CADL) 
PDF Net loss per share of $0.33. More on Candel Therapeutics Candel Therapeutics: A Low-Price Oncolytic Virus Play Further Along Than You Think Financial information [Read more]